Chicago, IL, United States of America

Ali Shilatifard

USPTO Granted Patents = 7 

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2018-2023

Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Ali Shilatifard

Introduction

Ali Shilatifard is a prominent inventor based in Chicago, IL (US). He has made significant contributions to the field of cancer research, holding a total of 7 patents. His work focuses on therapeutic strategies that target specific biological complexes involved in cancer progression.

Latest Patents

One of his latest patents is titled "Therapeutic targeting of the BAP1 complex in cancer." This patent discloses methods, compounds, and compositions for treating cancers characterized by therapeutic targeting of the BAP1 histone H2A deubiquitinase (DUB) complex. The methods and compounds aim to inhibit the biological activity of the BAP1 complex, particularly for treating cancers such as myeloid neoplasms. Another significant patent is "Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy." This patent reveals compounds that can inhibit transcription by RNA Polymerase II (Pol II) and disrupt the Super Elongation Complex (SEC). These compounds are intended for use in pharmaceutical compositions and methods for treating diseases associated with high levels of SEC-dependent gene expression, including various cancers.

Career Highlights

Ali Shilatifard is affiliated with Northwestern University, where he conducts his research and develops innovative therapeutic strategies. His work has garnered attention for its potential impact on cancer treatment and understanding the underlying mechanisms of cancer biology.

Collaborations

He has collaborated with notable colleagues, including Kaiwei Liang and Edwin Richard Smith, to advance research in his field. Their combined expertise contributes to the development of novel therapeutic approaches.

Conclusion

Ali Shilatifard's innovative work in cancer research exemplifies the importance of targeted therapies in modern medicine. His contributions through patents and collaborations continue to pave the way for advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…